Accelerated Approval’s Double-Edged Sword Cuts Down Agenus’ Balstilimab BLA

With US FDA’s early conversion of Merck’s Keytruda to full approval for chemotherapy-experienced cervical cancer, Agenus lost its expedited path to market and has opted to focus on development of combination treatments instead.

Russian Naval Dagger. Alamy-CPJP8D
US FDA's accelerated approval pathway offers unique benefits and vulnerabilities for sponsors. • Source: Alamy

The crowd of novel PD-1/L1 inhibitors seeking FDA approval shrank by one on 22 October 2021, when Agenus Inc. announced the withdrawal of its biologics license application for accelerated approval of balstilimab for recurrent or metastatic cervical cancer patients with disease progression on or after chemotherapy.

The precipitating factor was the FDA’s 13 October conversion from accelerated to full approval of a chemotherapy-experienced PD-L1-positive cervical cancer...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards